Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

Early Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: LPS

First Posted Date: 2019-08-15

Last Posted Date: 2024-02-05

Lead Sponsor: Yale University

Target Recruit Count: 18

Registration Number: NCT04057807

Locations: 🇺🇸
Alzheimer's Disease Research Unit, New Haven, Connecticut, United States

Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

Terminated

Conditions: Hepatitis C
Liver Transplant; Complications

First Posted Date: 2019-08-14

Last Posted Date: 2023-08-25

Lead Sponsor: Yale University

Target Recruit Count: 49

Registration Number: NCT04057001

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

A Virtual Reality Videogame for E-cigarette Prevention in Teens

Not Applicable

Completed

Conditions: E-Cig Use
Vaping

Interventions: Other: treatment as usual
Device: videogame

First Posted Date: 2019-08-13

Last Posted Date: 2021-06-25

Lead Sponsor: Yale University

Target Recruit Count: 287

Registration Number: NCT04054765

Locations: 🇺🇸
Milford School District, Milford, Connecticut, United States

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: ACUTE MYELOID LEUKEMIA

Interventions: Drug: Glasdegib
Drug: Decitabine

First Posted Date: 2019-08-09

Last Posted Date: 2021-10-15

Lead Sponsor: Yale University

Target Recruit Count: 1

Registration Number: NCT04051996

Locations: 🇺🇸
Yale Cancer Center/Smilow, New Haven, Connecticut, United States

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions: Drug: AG-120
Drug: Nivolumab

First Posted Date: 2019-08-05

Last Posted Date: 2022-01-20

Lead Sponsor: Yale University

Registration Number: NCT04044209

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

Phase 2

Withdrawn

Conditions: Pancreas Adenocarcinoma

Interventions: Drug: Gemcitabine

First Posted Date: 2019-08-05

Last Posted Date: 2020-01-09

Lead Sponsor: Yale University

Registration Number: NCT04045730

A Team-based Approach to Improve Knowledge and Judgment Performance in Electronic Fetal Monitoring

Not Applicable

Completed

Conditions: Electronic Fetal Monitoring

Interventions: Behavioral: Team-based approach

First Posted Date: 2019-07-31

Last Posted Date: 2019-07-31

Lead Sponsor: Yale University

Target Recruit Count: 92

Registration Number: NCT04040257

Locations: 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Not Applicable

Completed

Conditions: Acute Kidney Injury

Interventions: Other: Kidney Action Team Recommendations

First Posted Date: 2019-07-31

Last Posted Date: 2024-06-10

Lead Sponsor: Yale University

Target Recruit Count: 4000

Registration Number: NCT04040296

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes

Phase 2

Completed

Conditions: Nicotine
E-liquid Flavors

Interventions: Drug: Nicotine 0 mg/mL
Drug: Nicotine 6 mg/mL
Drug: Nicotine 12 mg/mL
Drug: Nicotine 24 mg/mL
Other: 'Menthol' flavor
Other: 'Menthol/Mint' flavor
Other: 'Green Apple' flavor
Other: 'Watermelon' flavor
Other: 'Unflavored'

First Posted Date: 2019-07-30

Last Posted Date: 2024-08-05

Lead Sponsor: Yale University

Target Recruit Count: 54

Registration Number: NCT04038515

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Cognitive Function and Pain Threshold in People Who Are Methadone Maintained

Early Phase 1

Completed

Conditions: Pain

Interventions: Drug: Methadone

First Posted Date: 2019-07-19

Last Posted Date: 2021-07-20

Lead Sponsor: Yale University

Target Recruit Count: 27

Registration Number: NCT04027166

Locations: 🇺🇸
Veteran Affairs Hospital, West Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy